001     128752
005     20240228143346.0
024 7 _ |a 10.1158/0008-5472.CAN-15-2507
|2 doi
024 7 _ |a pmid:27635046
|2 pmid
024 7 _ |a 0008-5472
|2 ISSN
024 7 _ |a 0099-7013
|2 ISSN
024 7 _ |a 0099-7374
|2 ISSN
024 7 _ |a 1538-7445
|2 ISSN
024 7 _ |a altmetric:12016724
|2 altmetric
037 _ _ |a DKFZ-2017-04767
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Henrich, Kai-Oliver
|0 P:(DE-He78)a579ca2567736066534409e732b31c91
|b 0
|e First author
|u dkfz
245 _ _ |a Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas.
260 _ _ |a Philadelphia, Pa.
|c 2016
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521801621_16499
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The broad clinical spectrum of neuroblastoma ranges from spontaneous regression to rapid progression despite intensive multimodal therapy. This diversity is not fully explained by known genetic aberrations, suggesting the possibility of epigenetic involvement in pathogenesis. In pursuit of this hypothesis, we took an integrative approach to analyze the methylomes, transcriptomes, and copy number variations in 105 cases of neuroblastoma, complemented by primary tumor- and cell line-derived global histone modification analyses and epigenetic drug treatment in vitro We found that DNA methylation patterns identify divergent patient subgroups with respect to survival and clinicobiologic variables, including amplified MYCN Transcriptome integration and histone modification-based definition of enhancer elements revealed intragenic enhancer methylation as a mechanism for high-risk-associated transcriptional deregulation. Furthermore, in high-risk neuroblastomas, we obtained evidence for cooperation between PRC2 activity and DNA methylation in blocking tumor-suppressive differentiation programs. Notably, these programs could be re-activated by combination treatments, which targeted both PRC2 and DNA methylation. Overall, our results illuminate how epigenetic deregulation contributes to neuroblastoma pathogenesis, with novel implications for its diagnosis and therapy. Cancer Res; 76(18); 5523-37. ©2016 AACR.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a MYCN protein, human
|2 NLM Chemicals
650 _ 7 |a N-Myc Proto-Oncogene Protein
|2 NLM Chemicals
700 1 _ |a Bender, Sebastian
|b 1
700 1 _ |a Saadati, Maral
|0 P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74
|b 2
|u dkfz
700 1 _ |a Dreidax, Daniel
|0 P:(DE-He78)00d281bd33b8c1254cbe4f048dbfaa14
|b 3
|u dkfz
700 1 _ |a Gartlgruber, Moritz
|0 P:(DE-He78)5190aa0a28a0d3d663954c463290e4c1
|b 4
|u dkfz
700 1 _ |a Shao, Chunxuan
|0 P:(DE-He78)7e77b1ec44a0797f186de678c66f80a0
|b 5
|u dkfz
700 1 _ |a Herrmann, Carl
|0 P:(DE-He78)be4a5aeed7282c071b3ff43e9685c48c
|b 6
|u dkfz
700 1 _ |a Wiesenfarth, Manuel
|0 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
|b 7
|u dkfz
700 1 _ |a Parzonka, Martha
|0 P:(DE-He78)dacf3ae5691e2f948ac22db3979eb0b6
|b 8
|u dkfz
700 1 _ |a Wehrmann, Lea Karola
|0 P:(DE-He78)ba5aedddbac780e42631b1c4aa901535
|b 9
|u dkfz
700 1 _ |a Fischer, Matthias
|b 10
700 1 _ |a Duffy, David J
|b 11
700 1 _ |a Bell, Emma
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Torkov, Alica
|0 P:(DE-He78)d15f3f868096e6900e9bd78f787b9af5
|b 13
|u dkfz
700 1 _ |a Schmezer, Peter
|0 P:(DE-He78)141ce740f5d881812d2675147b72ecaf
|b 14
|u dkfz
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 15
|u dkfz
700 1 _ |a Höfer, Thomas
|0 P:(DE-He78)9dbe272aaadbdc810ab0bb291eae428e
|b 16
|u dkfz
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 17
|u dkfz
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 18
|u dkfz
700 1 _ |a Westermann, Frank
|0 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
|b 19
|e Last author
|u dkfz
773 _ _ |a 10.1158/0008-5472.CAN-15-2507
|g Vol. 76, no. 18, p. 5523 - 5537
|0 PERI:(DE-600)2036785-5
|n 18
|p 5523 - 5537
|t Cancer research
|v 76
|y 2016
|x 1538-7445
909 C O |o oai:inrepo02.dkfz.de:128752
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)a579ca2567736066534409e732b31c91
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)00d281bd33b8c1254cbe4f048dbfaa14
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)5190aa0a28a0d3d663954c463290e4c1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)7e77b1ec44a0797f186de678c66f80a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)be4a5aeed7282c071b3ff43e9685c48c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)dacf3ae5691e2f948ac22db3979eb0b6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)ba5aedddbac780e42631b1c4aa901535
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)d15f3f868096e6900e9bd78f787b9af5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)141ce740f5d881812d2675147b72ecaf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)9dbe272aaadbdc810ab0bb291eae428e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER RES : 2015
920 1 _ |0 I:(DE-He78)B087-20160331
|k B087
|l Neuroblastom Genomik
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
920 1 _ |0 I:(DE-He78)B080-20160331
|k B080
|l Theoretische Bioinformatik
|x 2
920 1 _ |0 I:(DE-He78)C010-20160331
|k C010
|l Epigenomik und Krebsrisikofaktoren
|x 3
920 1 _ |0 I:(DE-He78)B086-20160331
|k B086
|l Theoretische Systembiologie
|x 4
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 5
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 6
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B087-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)B080-20160331
980 _ _ |a I:(DE-He78)C010-20160331
980 _ _ |a I:(DE-He78)B086-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21